Commentary on "Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies" by Sievers et al.

Author(s):: Rissmann, R.; Zuiker, R.

Published: 2021
Publication type: Article / Letter to editor

Date issued: 2021-03-24
Language: English
Publisher: WILEY
Is part of: British Journal of Clinical Pharmacology (2021), Vol. 87, no. 7, p. 2633-2634
hdl: 1887/3249604
doi: 10.1111/bcp.14823